Bruce Robertson Net Worth

Bruce Robertson biography

Dr. Bruce C. Robertson Ph.D. serves as Independent Director of the Company. Since 2005, Dr. Robertson has served as Managing Director of H.I.G. Capital, LLC, a global private equity and investment firm. Dr. Robertson previously served as a Managing Director at Toucan Capital, an early-stage venture capital firm. Dr. Robertson serves as a member of the board of directors of Apollo Endosurgery, Inc., a medical device company. Dr. Robertson holds a B.S.E. in Chemical Engineering and B.A. in Mathematics from the University of Pennsylvania, an M.B.A. from Harvard Business School, and a Ph.D. in Chemical Engineering from the University of Delaware. Dr. Robertson’s medical and research background and his extensive experience as an investor in the medical technologies industry contributed to our Board's conclusion that he should serve as a director of our company.

What is the salary of Bruce Robertson?

As the Independent Director of Exagen Inc, the total compensation of Bruce Robertson at Exagen Inc is $16,875. There are 9 executives at Exagen Inc getting paid more, with Fortunato Rocca having the highest compensation of $1,627,720.

How old is Bruce Robertson?

Bruce Robertson is 57, he's been the Independent Director of Exagen Inc since 2019. There are 8 older and 6 younger executives at Exagen Inc. The oldest executive at Exagen Inc is James Tullis, 72, who is the Independent Director.

What's Bruce Robertson's mailing address?

Bruce's mailing address filed with the SEC is 1450 BRICKELL AVENUE, 31ST FLOOR, , MIAMI, FL, 33131.

Insiders trading at Exagen Inc

Over the last 5 years, insiders at Exagen Inc have traded over $8,628,989 worth of Exagen Inc stock and bought 556,568 units worth $6,283,309 . The most active insiders traders include James L L Tullis, Bio Exagen, L.P.H.I.G. Gpii..., and Jeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of $109,189. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth $77,570.

What does Exagen Inc do?

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Exagen Inc executives and stock owners

Exagen Inc executives and other stock owners filed with the SEC include:

• Fortunato Rocca,
  President, Chief Executive Officer and Director
• Fortunato Rocca,
  CEO, Pres & Director
• Kamal Adawi M.S., MBA,
  CFO & Corp. Sec.
• Dr. Debra Jeske Zack,
  Chief Medical Officer
• Kamal Adawi,
  Chief Financial Officer and Corporate Secretary
• Jeffrey Elliott,
  Independent Director
• Tina Nova,
  Independent Director
• Chet Burrell,
  Independent Director
• Brian Birk,
  Independent Chairman of the Board
• Bruce Robertson,
  Independent Director
• James Tullis,
  Independent Director
• Ebetuel Pallares,
  Independent Director
• Wendy Johnson,
  Independent Director
• Debra Zack,
  Chief Medical Officer
• Anja Kammesheidt,
  Chief Scientific Officer
• John Wegener,
  Sr. VP of Sales and Marketing
• Dr. Ming-Chou Lee Ph.D.,
  Chief Technology Officer
• Mark Hazeltine,
  Chief Operating Officer
• Frank Stokes,
  Director
• Scott D Kahn,
  Director
• Thierry Dervieux,
  Chief Scientific Officer
• James L Ltullis Growth Fund...,
  
• Bio Exagen, L.P.H.I.G. Gpii...,
  
• Dickerson Capital Focus Iii...,
  
• Holdings Limited Partnershi...,
  
• Co Investment Fund, L.P.Nms...,
  
• Paul Kim,
  Director
• Co Investment Fund, L.P.Sun...,
  
• Ana Hooker,
  Director
• John Aballi,
  President and CEO
• Mark Hazeltine,
  Chief Business Officer
• Jeffrey G. Black,
  Chief Financial Officer